Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05016908 · ClinicalTrials.gov registry record
Extracellular RNA Biomarkers of Duchenne Muscular Dystrophy
A clinical trial of Duchenne Muscular Dystrophy, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- 100
- Enrollment target
- 2
- Study locations
NCT05016908 is a study of Duchenne Muscular Dystrophy that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 100 participants, below the 410-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (76% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT05016908, a study of Duchenne Muscular Dystrophy, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 2
- Study locations
Study Summary
Current methods of measuring the response to new treatments for muscular dystrophies involve the examination of small pieces of muscle tissue called biopsies. The investigators are interested in finding less invasive methods that reduce the need for muscle biopsies. The purpose of this research is to learn about the possibility of detecting and measuring the activity and severity of muscular dystrophies by examining a urine sample and a blood sample.
Conditions Studied
Study Locations (2)
Massachusetts
- Boston Children's Hospital - Boston
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2019-11-30 |
| Est. Completion | 2027-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05016908
The ClinicalTrials.gov registry entry for NCT05016908 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 410-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (76% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Duchenne Muscular Dystrophy appearing as the primary indexed condition, and to 0 interventions.
NCT05016908 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05016908 about?
NCT05016908 is a clinical study titled "Extracellular RNA Biomarkers of Duchenne Muscular Dystrophy". Current methods of measuring the response to new treatments for muscular dystrophies involve the examination of small pieces of muscle tissue called biopsies. The investigators are interested in finding less invasive methods that reduce the need for muscle biopsies. The purpose of this research is t...
What is the current status of trial NCT05016908?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2019-11-30. Estimated completion is 2027-11.
What conditions does trial NCT05016908 study?
This clinical trial studies the following conditions: Duchenne Muscular Dystrophy.
Who is sponsoring clinical trial NCT05016908?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05016908 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Duchenne Muscular Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
RECRUITING · Phase 1
-
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 2
-
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
RECRUITING · Phase 2
-
Once Weekly Infant Corticosteroid Trial for DMD
RECRUITING · Phase 4
-
The Duchenne Registry
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.